The system, which received a CE mark last year and has been submitted for FDA clearance, is the latest version of Stereotaxis Genesis robotic magnetic navigation (RMN) system.
“We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital,” Stereotaxis CEO David Fischel said in a news release.
“Establishing the first GenesisX robotic lab is a critical milestone for us as we advance towards full commercial launch. We look forward to demonstrating the performance and reliability of GenesisX in the demanding clinical environment. GenesisX promises to transform the accessibility of robotic magnetic navigation and is central to our mission of driving broad robotic adoption throughout endovascular surgery.”
According to Stereotaxis, GenesisX uses magnets smaller than those used in previous Genesis systems. It also incorporates magnetic shielding into its structure in place of the shielding otherwise installed in the walls of the operating room.
Other GenesisX features include:
- It needs no structural anchoring through the floor;
- It uses standard 120/230V power outlets;
- A single fiber is routed from each robot to the system cabinet, which is 80% smaller than previous cabinets and can fit under a table in the operating room;
- GenesisX is smaller and lighter than any previous generation system, but it the company says it maintains the highest standards in speed, responsiveness, and efficient workflow.
Stereotaxis’ plans this year include gaining regulatory approvals in Europe and the U.S. for a portfolio of compatible EP and vascular catheters for Genesis X. The company plans to demonstrate, real-world use of GenesisX, enhance system compatibility with various X-rays, and prepare supply chain, manufacturing, installation and commercial processes for a full launch.
